SPYRE THERAPEUTICS, INC.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -78.4% | -78.4% | -59.9% |
| FY2022 | -166.6% | -166.6% | -117.8% |
| FY2023 | -184.1% | -184.1% | -99.1% |
| FY2024 | -40.2% | -40.2% | -34.2% |
| FY2025 | -21.7% | -21.7% | -20.0% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -78.4% | -78.4% | -59.9% |
| FY2022 | -166.6% | -166.6% | -117.8% |
| FY2023 | -184.1% | -184.1% | -99.1% |
| FY2024 | -40.2% | -40.2% | -34.2% |
| FY2025 | -21.7% | -21.7% | -20.0% |